Precision Biosciences (DTIL) Cash & Current Investments (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Cash & Current Investments data on file, last reported at $101.2 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $101.2 million, up 31.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.2 million (up 31.03% YoY), and the FY2025 annual result was $115.6 million, up 33.92% from the prior year.
• Cash & Current Investments retreated to $101.2 million in Q1 2026 per DTIL's latest filing, from $115.6 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $212.1 million in Q3 2022 and troughed at $44.9 million in Q3 2025.
• A 5-year average of $122.8 million and a median of $116.7 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments jumped 36.06% in 2023, then tumbled 55.66% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $189.6 million in 2022, then tumbled by 38.45% to $116.7 million in 2023, then declined by 26.03% to $86.3 million in 2024, then soared by 33.92% to $115.6 million in 2025, then fell by 12.46% to $101.2 million in 2026.
• Business Quant data shows DTIL's Cash & Current Investments at $101.2 million in Q1 2026, $115.6 million in Q4 2025, and $44.9 million in Q3 2025.